ArticleIn vivo (Athens, Greece)
Radiotherapy With Hyperthermia for Prostatic Ductal Adenocarcinoma: Primary and Salvage Cases.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimProstatic ductal adenocarcinoma (PDA) is a rare and aggressive histological variant of prostate cancer associated with a high risk of treatment failure and poor survival compared to conventional acinar adenocarcinoma. We report three cases of PDA treated with radiotherapy combined with regional hyperthermia. CASE REPORT: Two patients with locally advanced PDA (cT3aN0M0) were treated with definitive intensity-modulated radiotherapy combined with regional hyperthermia. One patient with biochemical recurrence following radical prostatectomy (pT3aN0M0) received salvage three-dimensional conformal radiotherapy with regional hyperthermia. Therapeutic heating was achieved in all cases, with thermal doses (CEM43T90) of 5.2, 6.1, and 2.3 min, respectively. Long-term clinical control was observed in all patients, with follow-up durations of six, nine, and eight years, respectively. In the salvage case, a secondary prostate-specific antigen increase occurred but was successfully controlled with short-term hormonal therapy, with no subsequent clinical progression.
conclusionRadiotherapy combined with regional hyperthermia may represent a promising treatment strategy for achieving durable clinical control in patients with PDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.